Table 2.

CRISPR in clinical practice.

Status	Name/Trial	Trade Name	Disease	Reference
2017 FDA approved	Voretigene neparvovec	Luxterna	Retinal dystrophy	[43,44]
2019 FDA approved	Onasemnogene abeparvovec	Zolgensma	SMA (Pediatric Patients, < 2 y/o)	[45,46]
Currently evaluated in clinical trials	Lovotibeglogene autotemcel	LentiGlobin BB305	SCD, Thalassemia, TDT	[47]
Currently evaluated in clinical trials	CLIMB THAL-111, CLIMB SCD-111	-	SCD, TDT	[48]